| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Impairment of right-of-use asset | - | 0 | - | - |
| Total other income/(expenses) | -75,678 | -88,388 | -19,541 | -9,403 |
| Net (loss) before provision for income taxes | -1,509,566 | -726,133 | -600,033 | -433,200 |
| Provision for income taxes | - | 0 | - | - |
| Net (loss) | -1,509,566 | -726,133 | -600,033 | -433,200 |
| Comprehensive income (loss), net of tax, attributable to parent | - | - | - | -433,200 |
| Net income (loss) per share - basic | 0 | 0 | 0 | 0 |
| Net income (loss) per share - diluted | 0 | 0 | 0 | 0 |
| Weighted average number of shares outstanding during the period - basic | 1,068,264,462 | 1,047,493,242 | 1,041,458,063 | 1,038,374,219 |
| Weighted average number of shares outstanding during the period - diluted | 1,068,264,462 | 1,047,493,242 | 1,041,458,063 | 1,038,374,219 |
Kraig Biocraft Laboratories, Inc. (KBLB)
Kraig Biocraft Laboratories, Inc. (KBLB)